GRO Biosciences
GRO Biosciences is a biotechnology company leveraging groundbreaking science to expand the amino acid alphabet and deliver on the promise of protein therapeutics. The company is focused on transforming treatments for autoimmune and metabolic diseases by developing protein therapeutics with unique non-standard amino acid (NSAA) chemistries, offering capabilities such as unprecedented duration of action and precise immune regulation. Founded in 2016 and headquartered in Cambridge, MA, GRO Biosciences aims to address the limitations of current protein therapies and create a new universe of designer proteins with enhanced therapeutic properties.
Industries
Nr. of Employees
small (1-50)
Products
ProGly-modified uricase enzyme for refractory gout
An investigational uricase enzyme engineered with glycan-containing non-standard amino acids to reduce anti-drug antibody formation and enable sustained control of serum uric acid.
Glycan-containing NSAA therapeutic platform (ProGly)
Platform chemistry comprising glycan-bearing non-standard amino acids for precise control of immune responses to protein therapeutics, used for immunotolerization or immune recruitment.
Duration-enhancing NSAA chemistries (DuraLogic)
NSAA-based chemistries designed to stabilize protein structure and extend duration of action, enabling altered pharmacodynamic profiles and less frequent dosing.
ProGly-modified uricase enzyme for refractory gout
An investigational uricase enzyme engineered with glycan-containing non-standard amino acids to reduce anti-drug antibody formation and enable sustained control of serum uric acid.
Glycan-containing NSAA therapeutic platform (ProGly)
Platform chemistry comprising glycan-bearing non-standard amino acids for precise control of immune responses to protein therapeutics, used for immunotolerization or immune recruitment.
Duration-enhancing NSAA chemistries (DuraLogic)
NSAA-based chemistries designed to stabilize protein structure and extend duration of action, enabling altered pharmacodynamic profiles and less frequent dosing.
Services
Platform-enabled discovery collaborations for NSAA proteins
Partnership engagements to apply the recoded-organism and biofoundry platform to discovery and preclinical development of NSAA-containing protein therapeutics.
Preclinical development and IND-enabling services for NSAA therapeutics
Preclinical study design and execution, immunogenicity assessment, and IND-enabling activities to support clinical entry of NSAA-containing protein therapeutics.
Platform-enabled discovery collaborations for NSAA proteins
Partnership engagements to apply the recoded-organism and biofoundry platform to discovery and preclinical development of NSAA-containing protein therapeutics.
Preclinical development and IND-enabling services for NSAA therapeutics
Preclinical study design and execution, immunogenicity assessment, and IND-enabling activities to support clinical entry of NSAA-containing protein therapeutics.
Expertise Areas
- Protein engineering with non-standard amino acids
- Genomic recoding and translational machinery engineering
- Computational protein design and biofoundry automation
- Bioprocess development and scale-up for biologics
Key Technologies
- Genomically recoded organisms (GROs)
- Non-standard amino acid (NSAA) incorporation
- tRNA and translational machinery engineering
- Computational protein design